{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:15Z","timestamp":1791397275964,"version":"4.3.3"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The Japanese Society for Helicobacter Research (JSHR) published the fifth edition of the guidelines for the management of\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ) infection in 2024 in Japanese language.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This edition of JSHR guidelines was first developed in accordance with the Minds Clinical Practice Guideline and Grading of Recommendations Assessment, Development, and Evaluation system. This was published after inviting public comments and external evaluations. Consensus on clinical questions (CQs) was achieved using the modified Delphi method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no change in the basic policy that all\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infectious diseases are indications for eradication. Nucleic acid amplification was added to the diagnostic methods. Effects of proton-pump inhibitors (PPIs) on diagnostic tests were updated. The superiority of potassium-competitive acid blockers to PPIs in 1-week triple therapy with amoxicillin and clarithromycin has been shown. A flowchart for eradication therapy was provided for use in real-world settings. For gastric cancer prevention, eradication in earlier age is recommended. The most appropriate test and treatment strategies for adolescents are also described. Some CQs concerning gastric cancer prevention were identified, although evidence level was insufficient to make recommendations based on clinical importance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The revised guidelines facilitate the appropriate management of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection and gastric cancer prevention.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-026-02379-4","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:23:22Z","timestamp":1774675402000},"page":"841-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-6525","authenticated-orcid":false,"given":"Hajime","family":"Isomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-0000","authenticated-orcid":false,"given":"Tadashi","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-4666","authenticated-orcid":false,"given":"Takako","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6953-6079","authenticated-orcid":false,"given":"Osamu","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntaro","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-5923","authenticated-orcid":false,"given":"Daisuke","family":"Chinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-7392","authenticated-orcid":false,"given":"Mitsushige","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-1291","authenticated-orcid":false,"given":"Soichiro","family":"Sue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-6415","authenticated-orcid":false,"given":"Koji","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-3384","authenticated-orcid":false,"given":"Toshihiro","family":"Nishishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-0405","authenticated-orcid":false,"given":"Osamu","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-595X","authenticated-orcid":false,"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-4671","authenticated-orcid":false,"given":"Hideki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5263-2868","authenticated-orcid":false,"given":"Masumi","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ikebuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-8746","authenticated-orcid":false,"given":"Yuji","family":"Nadatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5047-6195","authenticated-orcid":false,"given":"Ryota","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-0789","authenticated-orcid":false,"given":"Kazuo","family":"Yashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6504","authenticated-orcid":false,"given":"Tamaki","family":"Ikuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-5522","authenticated-orcid":false,"given":"Toshihiko","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2396-8036","authenticated-orcid":false,"given":"Momoko","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Mabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-5039","authenticated-orcid":false,"given":"Kazunari","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-6163","authenticated-orcid":false,"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"2379_CR1","volume-title":"Minds clinical practice guideline development manual 2020. ver. 3.0","author":"Minds guideline center","year":"2020","unstructured":"Minds guideline center. Minds clinical practice guideline development manual 2020. ver. 3.0. Tokyo: Japan Council for Quality Health Care; 2020."},{"key":"2379_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"2379_CR3","volume-title":"Kyoto classification of gastritis","author":"K Haruma","year":"2017","unstructured":"Haruma K, Kato M, Inoue K, et al. Kyoto classification of gastritis. 1st ed. Tokyo: Nihon Medical Center; 2017.","edition":"1"},{"key":"2379_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/den.13486","volume":"32","author":"S Yoshii","year":"2020","unstructured":"Yoshii S, Mabe K, Watano K, et al. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. Dig Endosc. 2020;32:74\u201383.","journal-title":"Dig Endosc"},{"key":"2379_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00535-022-01934-z","volume":"58","author":"K Yashima","year":"2023","unstructured":"Yashima K, Onoyama T, Kurumi H, et al. Current status and future perspective of linked color imaging for gastric cancer screening: a literature review. J Gastroenterol. 2023;58:1\u201313.","journal-title":"J Gastroenterol"},{"key":"2379_CR6","doi-asserted-by":"publisher","first-page":"e12597","DOI":"10.1111\/hel.12597","volume":"24","author":"M Kato","year":"2019","unstructured":"Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter. 2019;24:e12597.","journal-title":"Helicobacter"},{"key":"2379_CR7","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.3748\/wjg.v19.i45.8188","volume":"19","author":"T Shimoyama","year":"2013","unstructured":"Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:8188\u201391.","journal-title":"World J Gastroenterol"},{"key":"2379_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12961","volume":"28","author":"Y Kajihara","year":"2023","unstructured":"Kajihara Y, Shimoyama T, Mizuki I. Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing. Helicobacter. 2023;28:e12961.","journal-title":"Helicobacter"},{"key":"2379_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3748\/wjg.14.1539","volume":"14","author":"J Yakoob","year":"2008","unstructured":"Yakoob J, Rasool S, Abbas Z, et al. Gastric juice for the diagnosis of H pylori infection in patients on proton pump inhibitors. World J Gastroenterol. 2008;14:1539\u201343.","journal-title":"World J Gastroenterol"},{"key":"2379_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00535-004-1356-3","volume":"39","author":"S Ohara","year":"2004","unstructured":"Ohara S, Kato M, Saito M, et al. Comparison between a new 13C-urea breath test, using a film-coated tablet, and the conventional 13C-urea breath test for the detection of Helicobacter pylori infection. J Gastroenterol. 2004;39:621\u20138.","journal-title":"J Gastroenterol"},{"key":"2379_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00535-003-1357-7","volume":"39","author":"M Kato","year":"2004","unstructured":"Kato M, Saito M, Fukuda S, et al. 13C-urea breath test, using a new compact nondispersive isotope-selective infrared spectrophotometer: comparison with mass spectrometry. J Gastroenterol. 2004;39:629\u201334.","journal-title":"J Gastroenterol"},{"key":"2379_CR12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1046\/j.1440-1746.2003.03193.x","volume":"18","author":"C Kato","year":"2003","unstructured":"Kato C, Sugiyama T, Sato K, et al. Appropriate cut-off value of 13C-urea breath test after eradication of Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2003;18:1379\u201383.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1440-1746.2006.04278.x","volume":"21","author":"Y Urita","year":"2006","unstructured":"Urita Y, Hike K, Torii N, et al. Influence of urease activity in the intestinal tract on the results of 13C-urea breath test. J Gastroenterol Hepatol. 2006;21:744\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1046\/j.1440-1746.2003.02922.x","volume":"18","author":"K Adachi","year":"2003","unstructured":"Adachi K, Fujishiro H, Mihara T, et al. Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18:168\u201371.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1128\/JCM.42.2.627-630.2004","volume":"42","author":"TTH Hoang","year":"2004","unstructured":"Hoang TTH, Wheeldon TU, Bengtsson C, et al. Enzyme-linked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated. J Clin Microbiol. 2004;42:627\u201330.","journal-title":"J Clin Microbiol"},{"key":"2379_CR16","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2018.180918","author":"M Kodama","year":"2019","unstructured":"Kodama M, Okimoto T, Mizukami K, et al. Evaluation of a novel anti-H. pylori antibody detection kit by latex turbidimetric immunoassay. Clin Lab. 2019. https:\/\/doi.org\/10.7754\/Clin.Lab.2018.180918.","journal-title":"Clin Lab"},{"key":"2379_CR17","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.3748\/wjg.v28.i43.6078","volume":"28","author":"O Toyoshima","year":"2022","unstructured":"Toyoshima O, Nishizawa T. Kyoto classification of gastritis: advances and future perspectives in endoscopic diagnosis of gastritis. World J Gastroenterol. 2022;28:6078\u201389.","journal-title":"World J Gastroenterol"},{"key":"2379_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/2050640619825947","volume":"7","author":"T Nishizawa","year":"2019","unstructured":"Nishizawa T, Sakitani K, Suzuki H, et al. A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H. pylori. United Eur Gastroenterol J. 2019;7:343\u20138.","journal-title":"United Eur Gastroenterol J"},{"key":"2379_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0140-6736(92)90929-W","volume":"339","author":"TU Kosunen","year":"1992","unstructured":"Kosunen TU, Sepp\u00e4l\u00e4 K, Sarna S, et al. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet. 1992;339:893\u20135.","journal-title":"Lancet"},{"key":"2379_CR20","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.2169\/internalmedicine.5132-20","volume":"59","author":"K Adachi","year":"2020","unstructured":"Adachi K, Kishi K, Notsu T, et al. Serum anti-Helicobacter pylori IgG antibody titer in H. pylori-negative cases with a different gastric mucosal atrophy status. Intern Med. 2020;59:2817\u201323.","journal-title":"Intern Med"},{"key":"2379_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13028","volume":"29","author":"T Okimoto","year":"2024","unstructured":"Okimoto T, Ando T, Sasaki M, et al. Antimicrobial-resistant Helicobacter pylori in Japan: report of nationwide surveillance for 2018\u20132020. Helicobacter. 2024;29:e13028.","journal-title":"Helicobacter"},{"key":"2379_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.15403\/jgld-222","volume":"28","author":"T Shinmura","year":"2019","unstructured":"Shinmura T, Adachi K, Yamaguchi Y, et al. Vonoprazan-based triple-therapy could improve efficacy of the tailored therapy of Helicobacter pylori infection. J Gastrointestin Liver Dis. 2019;28:389\u201395.","journal-title":"J Gastrointestin Liver Dis"},{"key":"2379_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12698","volume":"25","author":"R Horie","year":"2020","unstructured":"Horie R, Handa O, Ando T, et al. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter. 2020;25:e12698.","journal-title":"Helicobacter"},{"key":"2379_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12933","volume":"27","author":"M Tsuda","year":"2022","unstructured":"Tsuda M, Watanabe Y, Oikawa R, et al. Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid. Helicobacter. 2022;27:e12933.","journal-title":"Helicobacter"},{"key":"2379_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240040","volume":"15","author":"T Takayama","year":"2020","unstructured":"Takayama T, Suzuki H, Okada K, et al. Prediction of true Helicobacter pylori-uninfected status using a combination of age, serum antibody and pepsinogen: logistic regression analysis. PLoS ONE. 2020;15:e0240040.","journal-title":"PLoS ONE"},{"key":"2379_CR26","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1007\/s10620-022-07471-2","volume":"67","author":"JH Jeong","year":"2022","unstructured":"Jeong JH, Lee SY, Kim JH, et al. Useful serum pepsinogen levels for detecting ongoing Helicobacter pylori infection in asymptomatic subjects: a cross-sectional study based on 13C-urea breath test findings. Dig Dis Sci. 2022;67:5602\u20139.","journal-title":"Dig Dis Sci"},{"key":"2379_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cgh.2010.12.009","volume":"9","author":"L Gatta","year":"2011","unstructured":"Gatta L, Di Mario F, Vaira D, et al. Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin Gastroenterol Hepatol. 2011;9:440\u20132.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2379_CR28","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1023\/A:1018873717985","volume":"42","author":"M P\u00e9rez-Paramo","year":"1997","unstructured":"P\u00e9rez-Paramo M, Albillos A, Calleja JL, et al. Changes in gastrin and serum pepsinogens in monitoring of Helicobacter pylori response to therapy. Dig Dis Sci. 1997;42:1734\u201340.","journal-title":"Dig Dis Sci"},{"key":"2379_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1098-2825(1996)10:1<1::AID-JCLA1>3.0.CO;2-H","volume":"10","author":"M Plebani","year":"1996","unstructured":"Plebani M, Basso D, Scrigner M, et al. Serum pepsinogen C: a useful marker of Helicobacter pylori eradication? J Clin Lab Anal. 1996;10:1\u20135.","journal-title":"J Clin Lab Anal"},{"key":"2379_CR30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1046\/j.1365-2036.2000.00810.x","volume":"14","author":"K Kihira","year":"2000","unstructured":"Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1083\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s005350070077","volume":"35","author":"H Miwi","year":"2000","unstructured":"Miwi H, Murai T, Sato K, et al. Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol. 2000;35:536\u20139. https:\/\/doi.org\/10.1007\/s005350070077.","journal-title":"J Gastroenterol"},{"key":"2379_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1046\/j.1523-5378.2001.00037.x","volume":"6","author":"M Asaka","year":"2001","unstructured":"Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001;6:254\u201361.","journal-title":"Helicobacter"},{"key":"2379_CR33","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1365-2036.2002.01368.x","volume":"16","author":"K Murakami","year":"2002","unstructured":"Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2002;16:1933\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1067\/mcp.2002.125559","volume":"72","author":"H Ushiama","year":"2002","unstructured":"Ushiama H, Echizen H, Nachi S, et al. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002;72:33\u201343.","journal-title":"Clin Pharmacol Ther"},{"key":"2379_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00044011-200626070-00002","volume":"26","author":"K Higuchi","year":"2006","unstructured":"Higuchi K, Maekawa T, Nakagawa K, et al. Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. Clin Drug Investig. 2006;26:403\u201314.","journal-title":"Clin Drug Investig"},{"key":"2379_CR36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1365-2036.2007.03298.x","volume":"25","author":"H Kuwayama","year":"2007","unstructured":"Kuwayama H, Asaka M, Sugiyama T, et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther. 2007;25:1105\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR37","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439\u201346.","journal-title":"Gut"},{"key":"2379_CR38","first-page":"CD008337","volume":"2013","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2023;2013:CD008337.","journal-title":"Cochrane Database Syst Rev"},{"key":"2379_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","journal-title":"Gut"},{"key":"2379_CR40","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730\u201353 (EPub 2024\/12\/03).","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 11","key":"2379_CR41","first-page":"76","volume":"34","author":"K Kiyota","year":"1999","unstructured":"Kiyota K, Habu Y, Sugano Y, et al. Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. J Gastroenterol. 1999;34(Suppl 11):76\u20139.","journal-title":"J Gastroenterol"},{"key":"2379_CR42","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1111\/jgh.15700","volume":"36","author":"C Bunchorntavakul","year":"2021","unstructured":"Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol. 2021;36:3308\u201313.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2018.03.028","volume":"155","author":"WK Leung","year":"2018","unstructured":"Leung WK, Wong IOL, Cheung KS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155:67\u201375.","journal-title":"Gastroenterology"},{"key":"2379_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000022000","volume":"44","author":"A Pilotto","year":"1998","unstructured":"Pilotto A, Franceschi M, Di Mario F, et al. The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease. Gerontology. 1998;44:153\u20138.","journal-title":"Gerontology"},{"key":"2379_CR45","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(22)01843-8","volume":"400","author":"C Hawkey","year":"2022","unstructured":"Hawkey C, Avery A, Coupland CAC, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022;400:1597\u2013606.","journal-title":"Lancet"},{"key":"2379_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016619","volume":"98","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Joshita S, Yamamoto C, et al. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection. Medicine. 2019;98:e16619.","journal-title":"Medicine"},{"key":"2379_CR47","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s10620-022-07795-z","volume":"68","author":"A Kowada","year":"2023","unstructured":"Kowada A. A population-based Helicobacter pylori eradication strategy is more cost-effective than endoscopic screening. Dig Dis Sci. 2023;68:1735\u201346.","journal-title":"Dig Dis Sci"},{"key":"2379_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/apt.17070","volume":"56","author":"D Ang","year":"2022","unstructured":"Ang D, Koo SH, Chan YH, et al. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022;56:436\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163:608\u201319.","journal-title":"Gastroenterology"},{"key":"2379_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12456","volume":"23","author":"S Sue","year":"2018","unstructured":"Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter. 2018;23:e12456.","journal-title":"Helicobacter"},{"key":"2379_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035610","volume":"102","author":"F Yang","year":"2023","unstructured":"Yang F, Yu B, Qin L, et al. A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori. Medicine. 2023;102:e35610.","journal-title":"Medicine"},{"key":"2379_CR52","first-page":"127","volume":"19","author":"M Sasaki","year":"2018","unstructured":"Sasaki M, Maekawa T, Nishibayashi H, et al. The effect of clarithromycin-resistance on the eradication therapy of Helicobacter pylori\u2014Multicenter retrospective study. Jpn J Helicobacter Res Gakkai Zasshi. 2018;19:127\u201332.","journal-title":"Jpn J Helicobacter Res Gakkai Zasshi"},{"key":"2379_CR53","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.medmal.2019.06.001","volume":"50","author":"JC Delchier","year":"2020","unstructured":"Delchier JC, Bastuji-Garin S, Raymond J, et al. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492\u20139.","journal-title":"Med Mal Infect"},{"key":"2379_CR54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/sj.clpt.6100043","volume":"81","author":"T Furuta","year":"2007","unstructured":"Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"2379_CR55","first-page":"S171","volume":"23","author":"T Kawai","year":"2008","unstructured":"Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol. 2008;23(Suppl 2):S171\u20134.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR56","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/infdis\/jit287","volume":"208","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208:1123\u201330.","journal-title":"J Infect Dis"},{"key":"2379_CR57","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1097\/MEG.0000000000000197","volume":"26","author":"M Martos","year":"2014","unstructured":"Martos M, Bujanda L, Salicio Y, et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380\u20134.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2379_CR58","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/ajg.2014.222","volume":"109","author":"CS Park","year":"2014","unstructured":"Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109:1595\u2013602.","journal-title":"Am J Gastroenterol"},{"key":"2379_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020543","volume":"9","author":"M Murata","year":"2020","unstructured":"Murata M, Sugimoto M, Mizuno H, et al. Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis. J Clin Med. 2020;9:543.","journal-title":"J Clin Med"},{"key":"2379_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","volume":"12","author":"M Sugimoto","year":"2007","unstructured":"Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12:317\u201323.","journal-title":"Helicobacter"},{"key":"2379_CR61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1523-5378.2006.00394.x","volume":"11","author":"T Matsuhisa","year":"2006","unstructured":"Matsuhisa T, Kawai T, Masaoka T, et al. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter. 2006;11:152\u20138.","journal-title":"Helicobacter"},{"key":"2379_CR62","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00535-017-1407-1","volume":"53","author":"H Suzuki","year":"2018","unstructured":"Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354\u201361.","journal-title":"J Gastroenterol"},{"key":"2379_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70010","volume":"30","author":"H Mori","year":"2025","unstructured":"Mori H, Nishizawa T, Morioka K, et al. Should metronidazole be included in second-line treatment after standard triple therapy for Helicobacter pylori?: a systematic review and meta-analysis of randomized controlled trials. Helicobacter. 2025;30:e70010.","journal-title":"Helicobacter"},{"key":"2379_CR64","doi-asserted-by":"publisher","first-page":"175628481985851","DOI":"10.1177\/1756284819858511","volume":"12","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H, Omata F, et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019;12:1756284819858511.","journal-title":"Therap Adv Gastroenterol"},{"key":"2379_CR65","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","volume":"11","author":"X Liang","year":"2013","unstructured":"Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2379_CR66","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1046\/j.1523-5378.2003.00158.x","volume":"8","author":"S Miehlke","year":"2003","unstructured":"Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high\u2010dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003;8:310\u20139.","journal-title":"Helicobacter"},{"key":"2379_CR67","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2036.2006.02993.x","volume":"24","author":"S Miehlke","year":"2006","unstructured":"Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006;24:395\u2013403.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR68","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/jac\/dky056","volume":"73","author":"Y Xie","year":"2018","unstructured":"Xie Y, Pan X, Li Y, et al. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. J Antimicrob Chemother. 2018;73:1681\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"2379_CR69","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/jgh.14456","volume":"34","author":"S Sue","year":"2019","unstructured":"Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34:686\u201392.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR70","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/jgh.12442","volume":"29","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Kodaira C, et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2014;29:487\u201393.","journal-title":"J Gastroenterol Hepatol"},{"key":"2379_CR71","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/hel.12286","volume":"21","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter. 2016;21:286\u201394.","journal-title":"Helicobacter"},{"key":"2379_CR72","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/2050640615618043","volume":"4","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. U Eur Gastroenterol J. 2016;4:380\u20137.","journal-title":"U Eur Gastroenterol J"},{"key":"2379_CR73","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00535-012-0731-8","volume":"48","author":"K Murakami","year":"2013","unstructured":"Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48:1128\u201335.","journal-title":"J Gastroenterol"},{"key":"2379_CR74","volume":"2014","author":"K Okimoto","year":"2014","unstructured":"Okimoto K, Arai M, Saito K, et al. Efficacy of levofloxacin based triple and high-dose PPI-amoxicillin dual eradication therapy for Helicobacter pylori after failures of first- and second-line therapies. Int Sch Res Not. 2014;2014:631501.","journal-title":"Int Sch Res Not"},{"key":"2379_CR75","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","volume":"101","author":"T Furuta","year":"2020","unstructured":"Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020;101:743\u201351.","journal-title":"Digestion"},{"key":"2379_CR76","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-4133","volume":"10","author":"Y Lin","year":"2022","unstructured":"Lin Y, Xu H, Yun J, et al. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study. Ann Transl Med. 2022;10:987.","journal-title":"Ann Transl Med"},{"key":"2379_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13019","volume":"28","author":"S Ratana-Amornpin","year":"2023","unstructured":"Ratana-Amornpin S, Sanglutong L, Eiamsitrakoon T, et al. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023;28:e13019.","journal-title":"Helicobacter"},{"key":"2379_CR78","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019\u201326.","journal-title":"Gut"},{"key":"2379_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59621-3","volume":"14","author":"N Tungtrongchitr","year":"2024","unstructured":"Tungtrongchitr N, Bongkotvirawan P, Ratana-Amornpin S, et al. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024;14:8986.","journal-title":"Sci Rep"},{"key":"2379_CR80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jgh3.12852","volume":"7","author":"S Sue","year":"2023","unstructured":"Sue S, Kondo M, Sato T, et al. Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: a single-arm, interventional study. JGH Open. 2023;7:55\u201360.","journal-title":"JGH Open"},{"key":"2379_CR81","doi-asserted-by":"publisher","first-page":"2019802","DOI":"10.1155\/2017\/2019802","volume":"2017","author":"S Sue","year":"2017","unstructured":"Sue S, Suzuki N, Shibata W, et al. First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin. Gastroenterol Res Pract. 2017;2017:2019802.","journal-title":"Gastroenterol Res Pract"},{"key":"2379_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12374","author":"S Ono","year":"2017","unstructured":"Ono S, Kato M, Nakagawa S, et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017. https:\/\/doi.org\/10.1111\/hel.12374.","journal-title":"Helicobacter"},{"key":"2379_CR83","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2169\/internalmedicine.0789-22","volume":"62","author":"K Adachi","year":"2023","unstructured":"Adachi K, Kato S, Koshino A, et al. A vonoprazan, clarithromycin, and metronidazole regimen as Helicobacter pylori eradication therapy for patients with penicillin allergy in light of clarithromycin resistance. Intern Med. 2023;62:2301\u20136.","journal-title":"Intern Med"},{"key":"2379_CR84","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jgh3.12492","volume":"5","author":"S Sue","year":"2021","unstructured":"Sue S, Sasaki T, Kaneko H, et al. Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. JGH Open. 2021;5:307\u201311.","journal-title":"JGH Open"},{"key":"2379_CR85","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/2050640616688995","volume":"5","author":"H Mori","year":"2017","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al. Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients. U Eur Gastroenterol J. 2017;5:796\u2013804.","journal-title":"U Eur Gastroenterol J"},{"key":"2379_CR86","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1046\/j.1365-2036.2003.01527.x","volume":"17","author":"BS Sheu","year":"2003","unstructured":"Sheu BS, Huang JJ, Yang HB, et al. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. Aliment Pharmacol Ther. 2003;17:1283\u201390.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR87","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/jcm13030850","volume":"13","author":"T Nishizawa","year":"2024","unstructured":"Nishizawa T, Sano M, Toyoshima O, et al. Helicobacter pylori eradication therapy in patients with decreased renal function: a systematic review. J Clin Med. 2024;13:850.","journal-title":"J Clin Med"},{"key":"2379_CR88","first-page":"427","volume":"9","author":"M Alimadadi","year":"2015","unstructured":"Alimadadi M, Seyyedmajidi M, Amirkhanlou S, et al. Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. Iran J Kidney Dis. 2015;9:427\u201332.","journal-title":"Iran J Kidney Dis"},{"key":"2379_CR89","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajg.2011.07.004","volume":"12","author":"M Seyyedmajidi","year":"2011","unstructured":"Seyyedmajidi M, Falaknazi K, Mirsattari D, et al. Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: a randomised clinical trial. Arab J Gastroenterol. 2011;12:150\u20133.","journal-title":"Arab J Gastroenterol"},{"key":"2379_CR90","doi-asserted-by":"publisher","first-page":"3762194","DOI":"10.1155\/2017\/3762194","volume":"2017","author":"CM Liang","year":"2017","unstructured":"Liang CM, Chiu CH, Wang HM, et al. First-line Helicobacter pylori eradication in patients with chronic kidney diseases in Taiwan. BioMed Res Int. 2017;2017:3762194.","journal-title":"BioMed Res Int"},{"key":"2379_CR91","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/pgmj.50.586.500","volume":"50","author":"DH Lawson","year":"1974","unstructured":"Lawson DH, Henderson AK, McGeachy RR. Amoxycillin: pharmacokinetic studies in normal subjects, patients with pernicious anaemia and those with renal failure. Postgrad Med J. 1974;50:500\u20133.","journal-title":"Postgrad Med J"},{"key":"2379_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13106","volume":"29","author":"S Sahara","year":"2024","unstructured":"Sahara S, Sugimoto M, Murata M, et al. Eradication therapy for Helicobacter pylori infection in patients receiving hemodialysis: review. Helicobacter. 2024;29:e13106.","journal-title":"Helicobacter"},{"key":"2379_CR93","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3164\/jcbn.25-68","volume":"77","author":"H Mori","year":"2025","unstructured":"Mori H, Iino C, Fujieda T. Targeting Helicobacter pylori in liver-impaired populations: a systematic review of efficacy and safety. J Clin Biochem Nutr. 2025;77:203\u20138.","journal-title":"J Clin Biochem Nutr"},{"issue":"Suppl 1","key":"2379_CR94","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1046\/j.1365-2036.2000.014s1216.x","volume":"14","author":"T Azuma","year":"2000","unstructured":"Azuma T, Ito S, Suto H, et al. Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. Aliment Pharmacol Ther. 2000;14(Suppl 1):216\u201322.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR95","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5009\/gnl.2011.5.4.447","volume":"5","author":"N Furusyo","year":"2011","unstructured":"Furusyo N, Walaa AH, Eiraku K, et al. Treatment for eradication of Helicobacter pylori infection among chronic hepatitis C patients. Gut Liver. 2011;5:447\u201353.","journal-title":"Gut Liver"},{"key":"2379_CR96","doi-asserted-by":"publisher","first-page":"854","DOI":"10.14740\/jocmr2725w","volume":"8","author":"T Takashima","year":"2016","unstructured":"Takashima T, Enomoto H, Iwata Y, et al. Effects of Helicobacter pylori eradication on the platelet count in hepatitis C virus-infected patients. J Clin Med Res. 2016;8:854\u20138.","journal-title":"J Clin Med Res"},{"key":"2379_CR97","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.kjms.2016.05.012","volume":"32","author":"CE Tsai","year":"2016","unstructured":"Tsai CE, Liang CM, Lee CH, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32:397\u2013402.","journal-title":"Kaohsiung J Med Sci"},{"key":"2379_CR98","doi-asserted-by":"publisher","first-page":"387","DOI":"10.11150\/kansenshogakuzasshi1970.81.387","volume":"81","author":"K Imase","year":"2007","unstructured":"Imase K, Tanaka A, Tokunaga K, et al. Lactobacillus reuteri tablets suppress Helicobacter pylori infection\u2014a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi J Jpn Assoc Infect Dis. 2007;81:387\u201393.","journal-title":"Kansenshogaku Zasshi J Jpn Assoc Infect Dis"},{"key":"2379_CR99","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3164\/jcbn.20-37","volume":"67","author":"R Mukai","year":"2020","unstructured":"Mukai R, Handa O, Suyama Y, et al. Effectiveness of including probiotics to Helicobacter pylori eradication therapies. J Clin Biochem Nutr. 2020;67:102\u20134.","journal-title":"J Clin Biochem Nutr"},{"key":"2379_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109783","volume":"9","author":"T Terasawa","year":"2014","unstructured":"Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS ONE. 2014;9:e109783.","journal-title":"PLoS ONE"},{"key":"2379_CR101","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10198-017-0901-y","volume":"19","author":"S Saito","year":"2018","unstructured":"Saito S, Azumi M, Muneoka Y, et al. Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ. 2018;19:545\u201355.","journal-title":"Eur J Health Econ"},{"key":"2379_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200618","volume":"33","author":"S Tanaka","year":"2023","unstructured":"Tanaka S, Goto A, Yamagishi K, et al. Long-term response of Helicobacter pylori antibody titer after eradication treatment in middle-aged Japanese: JPHC-NEXT study. J Epidemiol. 2023;33:1\u20137.","journal-title":"J Epidemiol"},{"key":"2379_CR103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21147\/j.issn.1000-9604.2017.02.05","volume":"29","author":"T Wang","year":"2017","unstructured":"Wang T, Zhang Y, Su H, et al. Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China. Chin J Cancer Res. 2017;29:127\u201336.","journal-title":"Chin J Cancer Res"},{"key":"2379_CR104","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1523-5378.2008.00616.x","volume":"13","author":"JH Lee","year":"2008","unstructured":"Lee JH, Kim N, Chung JI, et al. Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. Helicobacter. 2008;13:288\u201394.","journal-title":"Helicobacter"},{"key":"2379_CR105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3164\/jcbn.19-30","volume":"65","author":"M Kodama","year":"2019","unstructured":"Kodama M, Okimoto T, Mizukami K, et al. Differences in Helicobacter pylori and CagA antibody changes after eradication between subjects developing and not developing gastric cancer. J Clin Biochem Nutr. 2019;65:71\u20135.","journal-title":"J Clin Biochem Nutr"},{"key":"2379_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2036.2004.01970.x","volume":"20 Suppl 1","author":"T Ohkusa","year":"2004","unstructured":"Ohkusa T, Miwa H, Nomura T, et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients. Aliment Pharmacol Ther. 2004;20 Suppl 1:25\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"2379_CR107","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1053\/j.gastro.2020.05.100","volume":"159","author":"RJ Huang","year":"2020","unstructured":"Huang RJ, Koh H, Hwang JH, et al. A summary of the 2020 gastric cancer summit at Stanford University. Gastroenterology. 2020;159:1221\u20136.","journal-title":"Gastroenterology"},{"key":"2379_CR108","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3748\/wjg.v26.i5.466","volume":"26","author":"O Toyoshima","year":"2020","unstructured":"Toyoshima O, Nishizawa T, Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J Gastroenterol. 2020;26:466\u201377.","journal-title":"World J Gastroenterol"},{"key":"2379_CR109","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1523-5378.2011.00889.x","volume":"16","author":"T Matsuo","year":"2011","unstructured":"Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415\u20139.","journal-title":"Helicobacter"},{"key":"2379_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9:19.","journal-title":"Nat Rev Dis Primers"},{"key":"2379_CR111","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353\u201367.","journal-title":"Gut"},{"key":"2379_CR112","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/cancers15051604","volume":"15","author":"YS Jung","year":"2023","unstructured":"Jung YS, Tran MTX, Song H, et al. Association between age at Helicobacter pylori eradication and the risk of gastric cancer stratified by family history of gastric cancer: a nationwide population-based study. Cancers (Basel). 2023;15:1604.","journal-title":"Cancers (Basel)"},{"key":"2379_CR113","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","volume":"150","author":"YC Lee","year":"2016","unstructured":"Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113-1124.e5.","journal-title":"Gastroenterology"},{"key":"2379_CR114","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1053\/j.gastro.2019.10.019","volume":"158","author":"S Kumar","year":"2020","unstructured":"Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158:527-536.e7.","journal-title":"Gastroenterology"},{"key":"2379_CR115","doi-asserted-by":"publisher","first-page":"dju116","DOI":"10.1093\/jnci\/dju116","volume":"106","author":"WQ Li","year":"2014","unstructured":"Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106:dju116.","journal-title":"J Natl Cancer Inst"},{"key":"2379_CR116","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1136\/gutjnl-2025-336027","volume":"74","author":"JM Liou","year":"2025","unstructured":"Liou JM, Malfertheiner P, Hong TC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II. Gut. 2025;74:1767\u201391.","journal-title":"Gut"},{"key":"2379_CR117","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.3390\/jcm12134363","volume":"12","author":"N Garc\u00eda-Morales","year":"2023","unstructured":"Garc\u00eda-Morales N, P\u00e9rez-A\u00edsa \u00c1, Fiorini G, et al. Helicobacter pylori diagnostic tests used in Europe: results of over 34,000 patients from the European registry on Helicobacter pylori management. J Clin Med. 2023;12:4363.","journal-title":"J Clin Med"},{"key":"2379_CR118","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-012-0536-9","volume":"47","author":"S Take","year":"2012","unstructured":"Take S, Mizuno M, Ishiki K, et al. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. J Gastroenterol. 2012;47:641\u20136.","journal-title":"J Gastroenterol"},{"key":"2379_CR119","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12852","volume":"26","author":"H Zhao","year":"2021","unstructured":"Zhao H, Yan P, Zhang N, et al. The recurrence rate of Helicobacter pylori in recent 10 years: a systematic review and meta-analysis. Helicobacter. 2021;26:e12852.","journal-title":"Helicobacter"},{"key":"2379_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282341","volume":"18","author":"M Kodama","year":"2023","unstructured":"Kodama M, Mizukami K, Hirashita Y, et al. Differences in clinical features and morphology between differentiated and undifferentiated gastric cancer after Helicobacter pylori eradication. PLoS ONE. 2023;18:e0282341.","journal-title":"PLoS ONE"},{"key":"2379_CR121","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000527476","volume":"104","author":"F Ishibashi","year":"2023","unstructured":"Ishibashi F, Suzuki S, Nagai M, et al. A close follow-up strategy in the short period of time after Helicobacter pylori eradication contributes to earlier detection of gastric cancer. Digestion. 2023;104:165\u201373.","journal-title":"Digestion"},{"key":"2379_CR122","first-page":"36","volume":"27","author":"T Gotoda","year":"2024","unstructured":"Gotoda T, Ishikawa H, Kusano C, et al. Randomized controlled trial comparing the costs of gastric cancer screening systems between serological risk-based upper gastrointestinal endoscopy and the existing barium photofluorography: gastric cancer screening labeled by serum examination in place of aged gastric cancer organized screening systems (Galapagos study). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2024;27:36\u201348.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"2379_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12696","volume":"25","author":"E Kaji","year":"2020","unstructured":"Kaji E, Yoden A, Otani M, et al. Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki City. Helicobacter. 2020;25:e12696.","journal-title":"Helicobacter"},{"key":"2379_CR124","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00535-019-01559-9","volume":"54","author":"T Kakiuchi","year":"2019","unstructured":"Kakiuchi T, Matsuo M, Endo H, et al. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report. J Gastroenterol. 2019;54:699\u2013707.","journal-title":"J Gastroenterol"},{"key":"2379_CR125","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00535-011-0450-6","volume":"46","author":"T Akamatsu","year":"2011","unstructured":"Akamatsu T, Ichikawa S, Okudaira S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353\u201360.","journal-title":"J Gastroenterol"},{"key":"2379_CR126","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/MPG.0000000000001594","volume":"64","author":"NL Jones","year":"2017","unstructured":"Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN\/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991\u20131003.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2379_CR127","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","volume":"69","author":"JM Liou","year":"2020","unstructured":"Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093\u2013112.","journal-title":"Gut"},{"key":"2379_CR128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000368807","volume":"91","author":"H Masuyama","year":"2015","unstructured":"Masuyama H, Yoshitake N, Sasai T, et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. Digestion. 2015;91:30\u20136.","journal-title":"Digestion"},{"key":"2379_CR129","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJMoa001999","volume":"345","author":"N Uemura","year":"2001","unstructured":"Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784\u20139.","journal-title":"N Engl J Med"},{"key":"2379_CR130","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/j.gastro.2022.03.039","volume":"163","author":"L Yan","year":"2022","unstructured":"Yan L, Chen Y, Chen F, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163:154-162.e3.","journal-title":"Gastroenterology"},{"key":"2379_CR131","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00535-022-01942-z","volume":"58","author":"T Kakiuchi","year":"2023","unstructured":"Kakiuchi T, Matsuo M, Endo H, et al. Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study. J Gastroenterol. 2023;58:196\u2013204.","journal-title":"J Gastroenterol"},{"key":"2379_CR132","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1442-200X.2002.01585.x","volume":"44","author":"M Okuda","year":"2002","unstructured":"Okuda M, Miyashiro E, Koike M, et al. Serodiagnosis of Helicobacter pylori infection is not accurate for children aged below 10. Pediatr Int. 2002;44:387\u201390.","journal-title":"Pediatr Int"},{"key":"2379_CR133","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1542\/peds.2005-2925","volume":"118","author":"RW Frenck Jr","year":"2006","unstructured":"Frenck RW Jr, Fathy HM, Sherif M, et al. Sensitivity and specificity of various tests for the diagnosis of Helicobacter pylori in Egyptian children. Pediatrics. 2006;118:e1195\u2013202.","journal-title":"Pediatrics"},{"key":"2379_CR134","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/MPG.0b013e3182077d33","volume":"52","author":"YA Leal","year":"2011","unstructured":"Leal YA, Cedillo-Rivera R, Sim\u00f3n JA, et al. Utility of stool sample-based tests for the diagnosis of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;52:718\u201328.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2379_CR135","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12329","author":"K Mabe","year":"2017","unstructured":"Mabe K, Kikuchi S, Okuda M, et al. Diagnostic accuracy of urine Helicobacter pylori antibody test in junior and senior high school students in Japan. Helicobacter. 2017. https:\/\/doi.org\/10.1111\/hel.12329.","journal-title":"Helicobacter"},{"key":"2379_CR136","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/ped.12057","volume":"55","author":"M Okuda","year":"2013","unstructured":"Okuda M, Kamiya S, Booka M, et al. Diagnostic accuracy of urine-based kits for detection of Helicobacter pylori antibody in children. Pediatr Int. 2013;55:337\u201341.","journal-title":"Pediatr Int"},{"key":"2379_CR137","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/ped.13286","volume":"59","author":"M Okuda","year":"2017","unstructured":"Okuda M, Mabe K, Lin Y, et al. Rapid urine antibody test for Helicobacter pylori infection in adolescents. Pediatr Int. 2017;59:798\u2013802.","journal-title":"Pediatr Int"},{"key":"2379_CR138","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ped.13038","volume":"59","author":"M Okuda","year":"2017","unstructured":"Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57\u201361.","journal-title":"Pediatr Int"},{"key":"2379_CR139","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12764","volume":"26","author":"E Miyata","year":"2021","unstructured":"Miyata E, Kudo T, Ikuse T, et al. Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: a single-center study over 12 years. Helicobacter. 2021;26:e12764.","journal-title":"Helicobacter"},{"key":"2379_CR140","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jiac.2018.02.013","volume":"24","author":"K Mabe","year":"2018","unstructured":"Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24:538\u201343.","journal-title":"J Infect Chemother"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02379-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02379-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02379-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:03:01Z","timestamp":1781953381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02379-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":140,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2379"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02379-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors, the spouse, partner, or immediate relatives of the authors have received individually any income, honoraria, or any other type of remuneration: Astellas Pharmaceutical, Otsuka Pharmaceutical, Takeda Pharmaceutical; (2) those from which the authors have received research grant: Nipro Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}